

US dollar amounts shown in the tables below are a convenience translation of the sterling amounts. These tables are unaudited.

Income statement

	YTD Q3 2023 £m	YTD Q3 2023 \$m
TURNOVER	22,276	27,651
Cost of sales	(6,147)	(7,630)
Gross profit	16,129	20,021
Selling, general and administration	(6,707)	(8,324)
Research and development	(4,176)	(5,184)
Royalty income	718	891
Other Operating income / (expense)	208	258
OPERATING PROFIT	6,172	7,662
Finance income	86	107
Finance expense	(570)	(709)
Share of after tax profit/(loss) of associates and joint venture	(4)	(5)
Profit/(loss) on disposal of interest in associates	1	1
PROFIT BEFORE TAXATION	5,685	7,057
Taxation	(775)	(962)
PROFIT AFTER TAXATION FOR THE PERIOD	4,910	6,095
Profit attributable to non-controlling interests	332	412
Profit attributable to shareholders	4,578	5,683
	4,910	6,095
EARNINGS PER SHARE	113.0p	140.3c
Diluted earnings per share	111.4p	138.3c

In the income statement above US dollar results for the nine months period ended 30 September 2023 are calculated using average rates for nine months ended 30 September 2023.

In the detailed sales tables below US dollar results for the nine months ended 30 September 2023 are calculated using average rates for nine months ended 30 September 2023

Vaccines turnover – nine months ended 30 September 2023

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Shingles	2,538	1,395	684	459	3,151	1,732	849	570
<i>Shingrix</i>	2,538	1,395	684	459	3,151	1,732	849	570
Meningitis	987	511	329	147	1,225	634	408	183
<i>Bexsero</i>	678	275	316	87	841	341	392	108
<i>Menveo</i>	293	236	9	48	364	293	11	60
<i>Other</i>	16	-	4	12	20	-	5	15
RSV	709	700	2	7	880	869	2	9
<i>Arexvy</i>	709	700	2	7	880	869	2	9
Influenza	409	318	21	70	508	395	26	87
<i>Fluarix, FluLaval</i>	409	318	21	70	508	395	26	87
Established Vaccines	2,495	1,005	552	938	3,098	1,249	685	1,164
<i>Infanrix, Pediarix</i>	407	224	79	104	505	278	98	129
<i>Boostrix</i>	472	316	92	64	586	393	114	79
<i>Hepatitis</i>	485	276	132	77	602	343	163	96
<i>Rotarix</i>	466	159	89	218	578	197	110	271
<i>Synflorix</i>	227	-	27	200	282	-	34	248
<i>Priorix, Priorix Tetra, Varilrix</i>	189	11	98	80	235	14	122	99
<i>Cervarix</i>	110	-	30	80	137	-	38	99
<i>Other</i>	139	19	5	115	173	24	6	143
Vaccines ex COVID	7,138	3,929	1,588	1,621	8,862	4,879	1,970	2,013
Pandemic vaccines	143	-	123	20	178	-	153	25
<i>Pandemic adjuvant</i>	143	-	123	20	178	-	153	25
Vaccines	7,281	3,929	1,711	1,641	9,040	4,879	2,123	2,038

Specialty Medicines turnover – nine months ended 30 September 2023

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
HIV	4,671	3,061	1,049	561	5,798	3,800	1,302	696
<i>Dolutegravir products</i>	3,963	2,472	957	534	4,920	3,069	1,188	663
<i>Tivicay</i>	1,037	588	199	250	1,287	730	247	310
<i>Triumeq</i>	1,139	782	214	143	1,415	971	266	178
<i>Juluca</i>	484	371	103	10	601	461	128	12
<i>Dovato</i>	1,303	731	441	131	1,617	907	547	163
<i>Rukobia</i>	82	76	5	1	102	95	6	1
<i>Cabenuva</i>	485	402	71	12	602	499	88	15
<i>Apretude</i>	97	97	-	-	120	120	-	-
Other	44	14	16	14	54	17	20	17
Respiratory / Immunology and Other	2,162	1,475	343	344	2,684	1,831	426	427
<i>Nucala</i>	1,184	686	281	217	1,470	852	349	269
<i>Benlysta</i>	960	788	73	99	1,192	978	91	123
Other	18	1	(11)	28	22	1	(14)	35
Oncology	487	233	219	35	605	290	272	43
<i>Zejula</i>	371	172	166	33	461	214	206	41
<i>Blenrep</i>	30	(2)	32	-	37	(3)	40	-
<i>Jemperli</i>	81	59	21	1	101	74	26	1
<i>Ojjaara</i>	4	4	-	-	5	5	-	-
Other	1	-	-	1	1	0	-	1
Specialty Medicines ex COVID	7,320	4,769	1,611	940	9,086	5,920	2,000	1,166
Pandemic	31	(1)	1	31	38	(1)	1	38
<i>Xevudy</i>	31	(1)	1	31	38	(1)	1	38
Specialty Medicines	7,351	4,768	1,612	971	9,124	5,919	2,001	1,204

General Medicines turnover – nine months ended 30 September 2023

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Respiratory	5,079	2,529	1,040	1,510	6,302	3,138	1,290	1,874
<i>Annuity Ellipta</i>	26	21	-	5	32	26	-	6
<i>Anoro Ellipta</i>	402	191	142	69	499	237	176	86
<i>Avamys/Veramyst</i>	250	-	45	205	310	-	56	254
<i>Flixotide/Flovent</i>	351	225	50	76	435	279	62	94
<i>Incruse Ellipta</i>	122	59	44	19	152	73	55	24
<i>Relvar/Breo Ellipta</i>	801	307	271	223	994	381	336	277
<i>Seretide/Advair</i>	863	263	191	409	1,071	326	237	508
<i>Trelegy Ellipta</i>	1,613	1,176	203	234	2,002	1,460	252	290
<i>Ventolin</i>	551	287	72	192	683	356	89	238
Other Respiratory	100	-	22	78	124	-	27	97
Other General Medicines	2,565	214	544	1,807	3,186	266	676	2,244
Dermatology	278	-	81	197	346	-	101	245
<i>Augmentin</i>	469	-	137	332	582	-	170	412
<i>Avodart</i>	272	-	87	185	338	-	108	230
<i>Lamictal</i>	327	145	83	99	406	180	103	123
Other	1,219	69	156	994	1,514	86	194	1,234
General Medicines	7,644	2,743	1,584	3,317	9,488	3,404	1,966	4,118

Commercial operations turnover – nine months ended 30 September 2023

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Commercial Operations turnover	22,276	11,440	4,907	5,929	27,652	14,202	6,090	7,360
<i>Commercial operations turnover ex COVID</i>	<i>22,102</i>	<i>11,441</i>	<i>4,783</i>	<i>5,878</i>	<i>27,436</i>	<i>14,203</i>	<i>5,936</i>	<i>7,297</i>

Balance sheet

	30-Sep-23 £m	30-Sep-23 \$m
ASSETS		
Non-current assets		
Property, plant and equipment	8,814	10,811
Right of use assets	640	785
Goodwill	6,973	8,553
Other intangible assets	15,295	18,761
Investments in associates and joint ventures	75	92
Other investments	1,067	1,309
Deferred tax asset	5,610	6,881
Other non-current assets	1,148	1,408
Total non-current assets	39,622	48,600
Current assets		
Inventories	5,480	6,721
Current tax recoverable	330	405
Trade and other receivables	8,544	10,480
Derivative financial instruments	143	175
Current equity investments	3,436	4,215
Liquid investments	70	86
Cash and cash equivalents	3,177	3,897
Assets held for sale	60	74
Total current assets	21,240	26,053
TOTAL ASSETS	60,862	74,653
LIABILITIES		
Current liabilities		
Short-term borrowings	(4,843)	(5,941)
Contingent consideration liabilities	(1,024)	(1,256)
Trade and other payables	(15,582)	(19,113)
Derivative financial instruments	(121)	(148)
Current tax payable	(286)	(351)
Short term provisions	(534)	(655)
Total current liabilities	(22,390)	(27,464)
Non-current liabilities		
Long-term borrowings	(15,993)	(19,617)
Corporation tax payable	(78)	(96)
Deferred tax liabilities	(402)	(493)
Pension and other post-employment benefits	(2,278)	(2,794)
Derivative financial instruments	(6)	(7)
Other provisions	(546)	(670)
Contingent consideration liabilities	(5,486)	(6,729)
Other non-current liabilities	(1,064)	(1,305)
Total non-current liabilities	(25,853)	(31,711)
TOTAL LIABILITIES	(48,243)	(59,175)
NET ASSETS	12,619	15,478
EQUITY		
Share capital	1,348	1,653
Share premium account	3,450	4,232
Retained earnings	7,017	8,607
Other reserves	1,318	1,617
Shareholders' equity	13,133	16,109
Non-controlling Interests	(514)	(631)
TOTAL EQUITY	12,619	15,478

US dollar amounts shown in the balance sheet above are calculated using closing rate at 30 September 2023.